Meglumine antimoniate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Meglumine antimoniate
- Accession Number
- DB13732
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Meglumine antimoniate (DB13732)
- Weight
- Average: 365.98
Monoisotopic: 365.00705 - Chemical Formula
- C7H18NO8Sb
- Synonyms
- Antimoniato de meglumina
- Glucantim
- Glucantime
- Meglumine antimonate
- Meglumine antimoniate
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Categories
- ATC Codes
- P01CB01 — Meglumine antimonate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Hexoses
- Alternative Parents
- Organic antimonates / 1,3-aminoalcohols / Secondary alcohols / Organic antimony salts / 1,2-aminoalcohols / Polyols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- 1,2-aminoalcohol / 1,3-aminoalcohol / Alcohol / Aliphatic acyclic compound / Amine / Hexose monosaccharide / Hydrocarbon derivative / Organic antimonate / Organic antimony salt / Organic metal salt show 11 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 75G4TW236W
- CAS number
- 133-51-7
- InChI Key
- XOGYVDXPYVPAAQ-SESJOKTNSA-M
- InChI
- InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1
- IUPAC Name
- (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; oxostibinic acid
- SMILES
- O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
References
- General References
- Not Available
- External Links
- ChemSpider
- 58479
- 319866
- ChEMBL
- CHEMBL239129
- Wikipedia
- Meglumine_antimoniate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Leishmaniasis, Cutaneous 1 4 Completed Treatment Localized Cutaneous Leishmaniasis 1 4 Completed Treatment Visceral Leishmaniasis 1 4 Terminated Treatment Visceral Leishmaniasis 1 3 Completed Treatment Leishmaniasis, Cutaneous 3 3 Not Yet Recruiting Treatment Cutaneous Leishmaniases 1 3 Terminated Treatment Leishmaniasis, Cutaneous 2 3 Unknown Status Treatment Leishmaniasis, Cutaneous 1 2 Completed Treatment Leishmaniasis 1 2 Completed Treatment Leishmaniasis, Cutaneous 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Parenteral 1.5 g Injection, solution Intramuscular 1.5 G/5ML Solution Intramuscular 1.5 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 240.0 mg/mL ALOGPS logP -2.4 ALOGPS logP -3.4 ChemAxon logS 0.09 ALOGPS pKa (Strongest Acidic) 12.65 ChemAxon pKa (Strongest Basic) 9.11 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 6 ChemAxon Polar Surface Area 113.18 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 44.84 m3·mol-1 ChemAxon Polarizability 19.52 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on June 23, 2017 14:47 / Updated on December 02, 2020 04:50